S A Kashchenko, K A Kormachenko, M G Musaelyan, D V Galenko, A N Salakhova
{"title":"[Identification of depression biomarkers: Prospects for use in clinical practice].","authors":"S A Kashchenko, K A Kormachenko, M G Musaelyan, D V Galenko, A N Salakhova","doi":"10.17116/jnevro202512505151","DOIUrl":null,"url":null,"abstract":"<p><p>Major depressive disorder (MDD) is one of the most common mental illnesses that poses a serious threat to public health. MDD is associated with various biological changes, such as increased inflammation, oxidative stress, dysregulation of the stress axis, and changes in growth factors. These changes may be used as potential biomarkers to facilitate more accurate diagnosis and effective treatment of depression. Recently, a growing interest has been in identifying biomarkers that could be objective indicators of the patient's condition, opening up new horizons for diagnosis and treatment and allowing a more personalized approach to each patient. This review covers current studies on biomarkers that can objectively indicate the patient's condition. Particular attention is paid to methods for detecting these biological markers and their prospects in clinical practice, including diagnosis, monitoring the effectiveness of therapy, and predicting relapses. Such approaches can significantly improve the treatment outcomes and quality of life of patients with depression.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 5","pages":"51-55"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/jnevro202512505151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Major depressive disorder (MDD) is one of the most common mental illnesses that poses a serious threat to public health. MDD is associated with various biological changes, such as increased inflammation, oxidative stress, dysregulation of the stress axis, and changes in growth factors. These changes may be used as potential biomarkers to facilitate more accurate diagnosis and effective treatment of depression. Recently, a growing interest has been in identifying biomarkers that could be objective indicators of the patient's condition, opening up new horizons for diagnosis and treatment and allowing a more personalized approach to each patient. This review covers current studies on biomarkers that can objectively indicate the patient's condition. Particular attention is paid to methods for detecting these biological markers and their prospects in clinical practice, including diagnosis, monitoring the effectiveness of therapy, and predicting relapses. Such approaches can significantly improve the treatment outcomes and quality of life of patients with depression.
期刊介绍:
Одно из старейших медицинских изданий России, основанное в 1901 году. Создание журнала связано с именами выдающихся деятелей отечественной медицины, вошедших в историю мировой психиатрии и неврологии, – С.С. Корсакова и А.Я. Кожевникова.
Широкий диапазон предлагаемых журналом материалов и разнообразие форм их представления привлекают внимание научных работников и врачей, опытных и начинающих медиков, причем не только неврологов и психиатров, но и специалистов смежных областей медицины.